Granules India
Granules India Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulations, and over-the-counter (OTC) products. Founded in 1984, the company has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities across India and a strong global presence in markets such as the United States and Europe. Granules India is renowned for its commitment to quality and innovation, offering a diverse range of core products that include paracetamol, ibuprofen, and metformin. The company’s unique approach to integrated manufacturing sets it apart, enabling cost-effective production while maintaining high standards. With a robust market position, Granules India has garnered recognition for its sustainable practices and has received multiple certifications from regulatory bodies, solidifying its reputation as a trusted partner in the pharmaceutical sector.
DitchCarbon Score
How does Granules India's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Granules India's score of 60 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Granules India's reported carbon emissions
In 2024, Granules India reported total greenhouse gas emissions of approximately 633,837,000 kg CO2e across all scopes. This includes about 56,254,000 kg CO2e from Scope 1, 31,632,000 kg CO2e from Scope 2, and a significant 633,837,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to achieve net-zero emissions by 2050, in alignment with the Science Based Targets initiative (SBTi) 1.5°C pathway. Granules India has established near-term targets to reduce absolute Scope 1 and 2 emissions by 42% by FY2030, using FY2023 as the baseline. Additionally, they plan to increase their sourcing of renewable electricity from 0% in FY2023 to 100% by FY2030. The company also aims to reduce Scope 3 emissions by 42% within the same timeframe. In terms of intensity reduction, Granules India has set annual targets to decrease greenhouse gas intensity by 5% year-on-year for both Scope 1 and Scope 2 emissions from 2021 to 2023. Furthermore, they have committed to a 20% reduction in energy intensity by FY2026-27. Overall, Granules India is actively working towards significant emissions reductions and sustainability goals, reflecting a strong commitment to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 54,831,700 | 00,000,000 | 00,000,000 |
| Scope 2 | 50,526,500 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Granules India is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
